J&J posts late-stage trial win for plaque psoriasis pill in psoriatic arthritis
josefkubes
Johnson & Johnson (JNJ) announced on Saturday that Icotyde, its FDA-approved therapy marketed with Protagonist Therapeutics (PTGX) for plaque psoriasis, succeeded in a late-stage trial for psoriatic arthritis.
With studies showing that up to 30% of patients with plaque PsO also
KioskNews shows a cleaned-up reading view extracted from the publisher’s page — the original always lives on their site, not ours.